{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:49:16Z","timestamp":1794455356975,"version":"4.9.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Andrology"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Extracorporeal shock wave therapy improves erectile function in patients with Peyronie\u2019s disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5\u2003mg once daily in the management of patients with Peyronie\u2019s disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4\u2003weeks (<jats:italic>n<\/jats:italic>\u2003=\u200350) or extracorporeal shock wave therapy plus tadalafil 5\u2003mg once daily for 4\u2003weeks (<jats:italic>n<\/jats:italic>\u2003=\u200350). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow\u2010up evaluations were performed after 12 and 24\u2003weeks. In both groups, at 12\u2003weeks follow\u2010up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24\u2003weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5\u2003mg once daily may represent a valid conservative strategy for the management of patients with Peyronie\u2019s disease and erectile dysfunction.<\/jats:p>","DOI":"10.1111\/j.1365-2605.2011.01226.x","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T16:00:37Z","timestamp":1321459237000},"page":"190-195","source":"Crossref","is-referenced-by-count":89,"title":["Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial"],"prefix":"10.1111","volume":"35","author":[{"given":"A.","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Creta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Verze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-000-0010-8"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382004000300004"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.048"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802498440"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.05955.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01104.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.24"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000099891.68488.4e"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000108060.30363.8d"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02241.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901247"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01527-3"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900912"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.20360.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00225-7"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.20113.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00270-9"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.05.012"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-009-2089-y"},{"key":"e_1_2_5_21_1","first-page":"317","article-title":"Peyronie\u2019s disease and impotence","volume":"56","author":"Pryor JP.","year":"1988","journal-title":"Acta Urol Belg"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900472"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00883.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2003.12.002"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65370-9"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300161173"}],"container-title":["International Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2605.2011.01226.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2605.2011.01226.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:50:04Z","timestamp":1698702604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2605.2011.01226.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1365-2605.2011.01226.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2605.2011.01226.x","archive":["Portico"],"relation":{},"ISSN":["0105-6263","1365-2605"],"issn-type":[{"value":"0105-6263","type":"print"},{"value":"1365-2605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]}}}